Last reviewed · How we verify
Estradiol vaginal ring
Estradiol vaginal ring is a Estrogen [EPC] Small molecule drug developed by Oregon Health and Science University. It is currently FDA-approved for Contraception.
Estradiol vaginal ring, marketed by Oregon Health and Science University, is positioned in the contraception market. A key strength is the protection of its composition patent, which expires in 2028, providing a period of exclusivity. The primary risk is the lack of revenue data, which may indicate limited commercial success or market penetration.
At a glance
| Generic name | Estradiol vaginal ring |
|---|---|
| Sponsor | Oregon Health and Science University |
| Drug class | Estrogen [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Contraception
Boxed warnings
- WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including Etonogestrel and ethinyl estradiol vaginal ring, should not be used by women who are over 35 years of age and smoke. [ see Contraindications ( 4 )] WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. Women over 35 years old who smoke should not use etonogestrel and ethinyl estradiol vaginal ring ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination hormonal contraceptive (CHC) use. ( 4 ) BOXED WARNING What is the most important information I should know about ETONOGESTREL and ETHINYL ESTRADIOL VAGINAL RING delivers 0.120 mg/0.015 mg per day ? Do not use etonogestrel and ethinyl estradiol vaginal ring if you smoke cigarettes and are over 35 years old. Smoking increases your risk of serious cardiovascular side effects (heart and blood vessel problems) from combination hormonal contraceptives (CHCs), including death from heart attack, blood clots or stroke. This risk increases with age and the number of cigarettes you smoke.
Common side effects
- Vaginitis
- Headache (including migraine)
- Mood changes (depression, mood swings, mood altered, depressed mood, affect lability)
- Device-related events (expulsion/discomfort/foreign body sensation)
- Nausea/vomiting
- Vaginal discharge
- Increased weight
- Vaginal discomfort
- Breast pain/discomfort/tenderness
- Dysmenorrhea
- Abdominal pain
- Acne
Serious adverse events
- Deep vein thrombosis
- Stroke/cerebrovascular accident
- Arterial thromboembolism
- Myocardial infarction
- Anaphylaxis
- Angioedema
- Anxiety
- Cholelithiasis
- Vomiting
- Aggravation of varicose veins
Drug interactions
- Phenytoin, Barbiturates, Carbamazepine, Bosentan, Felbamate, Griseofulvin, Oxcarbazepine, Rifampicin, Topiramate, Rifabutin, Rufinamide, Aprepitant, St. John's Wort
- Oral Amoxicillin, Doxycycline
- Atorvastatin
- Ascorbic Acid, Acetaminophen
- Itraconazole, Voriconazole, Fluconazole, Grapefruit Juice, Ketoconazole
- Vaginal Miconazole Nitrate
Key clinical trials
- Comparison of Oral Dydrogesterone and Vaginal Progesterone in Menopausal Hormone Therapy (NA)
- Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency (PHASE3)
- Postpartum Vaginal Estrogen for Breastfeeding Patients (PHASE4)
- Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (NA)
- Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (PHASE4)
- Vaginal Estradiol and Oral Guaifenesin in Clomiphene Ovulation Induction (NA)
- Effect of Vaginal Estrogen on Alterations in the Urine Microbiome of Menopausal Women With Overactive Bladder (PHASE4)
- REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estradiol vaginal ring CI brief — competitive landscape report
- Estradiol vaginal ring updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI
Frequently asked questions about Estradiol vaginal ring
What is Estradiol vaginal ring?
Estradiol vaginal ring is a Estrogen [EPC] drug developed by Oregon Health and Science University, indicated for Contraception.
What is Estradiol vaginal ring used for?
Estradiol vaginal ring is indicated for Contraception.
Who makes Estradiol vaginal ring?
Estradiol vaginal ring is developed and marketed by Oregon Health and Science University (see full Oregon Health and Science University pipeline at /company/oregon-health-and-science-university).
What drug class is Estradiol vaginal ring in?
Estradiol vaginal ring belongs to the Estrogen [EPC] class. See all Estrogen [EPC] drugs at /class/estrogen-epc.
What development phase is Estradiol vaginal ring in?
Estradiol vaginal ring is FDA-approved (marketed).
What are the side effects of Estradiol vaginal ring?
Common side effects of Estradiol vaginal ring include Vaginitis, Headache (including migraine), Mood changes (depression, mood swings, mood altered, depressed mood, affect lability), Device-related events (expulsion/discomfort/foreign body sensation), Nausea/vomiting, Vaginal discharge. Serious adverse events: Deep vein thrombosis, Stroke/cerebrovascular accident, Arterial thromboembolism, Myocardial infarction.
Related
- Drug class: All Estrogen [EPC] drugs
- Manufacturer: Oregon Health and Science University — full pipeline
- Indication: Drugs for Contraception
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing